Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Charlestown, Massachusetts 02129


Purpose:

The placebo effect is a phenomenon that has experienced major advances of its understanding in the last decade. However, mechanisms of placebo analgesia in chronic pain patients have yet to be compared to healthy subjects. The investigators study aims to investigate the magnitude of placebo response and related opioid release in patients that suffer from episodic migraines as compared to healthy controls. In particular, the investigators are looking to map brain activity during placebo analgesia using modern brain imaging techniques such as functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET). The investigators hypothesis is that placebo response and the availability of opioid receptors is reduced in chronic migraine patients.


Criteria:

Inclusion Criteria: - Migraine patients with aura with acute episodic migraine meeting the IHS Classification ICHD-II criteria, 3-14 migraines per month. - History of episodic migraine for at least 3 years - Ages 21-50 - Male or Female - Right Handed Matched healthy subjects will also be recruited. Exclusion Criteria: - Other significant disease (systemic or CNS) - Pregnancy - Claustrophobia - Weight >235 lbs (limit of MRI table) - Significant drug including alcohol history (> 7 glasses of alcohol per week) - Beck Depression Inventory II (BDI-II) score > 25 (moderate to severe depression) - Any metal implants incompatible with MRI (including dental bridges, crowns, retainers, orthodontic devices e.g. braces, IUDs, aneurysm clips or other devices, tattoos containing metallic ink, cardiac pacemakers, prosthetic hear valves, other prostheses, neurostimulator devices, implanted infusion pumps, exposure to shrapnel or metal filings, cochlear implants, etc.) - Previous significant research related exposure to ionizing radiation. - History of allergy or adverse reaction to opioids - Significant medical history of such as seizure disorder, diabetes, alcoholism, cardiac disease including coronary artery disease, psychiatric problems; drug addiction, respiratory problems, liver disease, etc. - Positive drug of abuse screen (excluding medications currently prescribed for their clinical condition, e.g. opioids, benzodiazepines, etc.) - Patients with migraine <72 hours prior to the experiments will not be included to ensure inter-ictal state. - Opioids or preventative medication such as topiramate, SSRIs etc.


NCT ID:

NCT01970943


Primary Contact:

Principal Investigator
David Borsook, MD, Ph.D
Children's Hospital Boston


Backup Contact:

N/A


Location Contact:

Charlestown, Massachusetts 02129
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.